CHD Risk Stratification Evaluations for Subjects With High Levels of Large HDL-P
AssigneeLipoScience, Inc.
InventorsJames D. Otvos, Irina Y. Shalaurova
Life of this patent
Estimating the term…
Abstract
Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
Claims26
A method of determining whether a subject with elevated concentrations of very large high density lipoprotein (HDL) particles (HDL-P) is at increased risk for a cardiac event and/or CHD, comprising:
- programmatically calculating at least one HDL interaction risk parameter associated with HDL content of a blood plasma or serum sample of the subject, the at least one HDL interaction risk parameter comprising at least two of HPVS, HPML, and HP/VL, where HPVS is a concentration of very small HDL-P subclasses, HPML is a concentration of medium and large HDL-P subclasses, and HPVL is a concentration of very large HDL-P subclasses.
6-8. (canceled)
10-12. (canceled)
A computer program product for stratifying CHD risk for patients with elevated concentrations of very large high density lipoprotein (HDL) particles (HDL-P), the computer program product comprising:
- a non-transitory computer readable storage medium having computer readable program code embodied in the medium, the computer-readable program code comprising:
- computer readable program code that obtains concentration measurements of at least twenty subpopulations of HDL-P subclasses in a blood plasma or serum sample;
- and
- computer readable program code that calculates at least one HDL interaction risk parameter associated with HDL content of a blood plasma or serum sample of the subject, the at least one HDL interaction risk parameter comprising at least two of HPVS, HPML, and HPVL, where HPVS is a concentration of very small HDL-P subclasses, HPML is a concentration of medium and large HDL-P subclasses, and HPVL is a concentration of very large HDL-P subclasses.
19-30. (canceled)
A system for analyzing CHD risk, comprising:
- a circuit comprising at least one processor configured to determine whether a subject with elevated concentrations of very large high density lipoprotein (HDL) particles (HDL-P) is at increased risk for a cardiac event and/or CHD, the at least one processor configured to
- calculate at least one HDL interaction risk parameter associated with HDL content of a blood plasma or serum sample of the subject, the at least one HDL interaction risk parameter comprising at least two of HPVS, HPML, and HPVL, where HPVS is a concentration of very small HDL-P subclasses, HPML is a concentration of medium and large HDL-P subclasses, and HPVL is a concentration of very large HDL-P subclasses.
34-35. (canceled)
39-42. (canceled)
45-56. (canceled)
Dependencies are inferred from the claim text.